Probiotics in the Management of Lung Diseases
The physiology and pathology of the respiratory and gastrointestinal tracts are closely related. This similarity between the two organs may underlie why dysfunction in one organ may induce illness in the other. For example, smoking is a major risk factor for COPD and IBD and increases the risk of de...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/751068 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849396699515060224 |
|---|---|
| author | Esmaeil Mortaz Ian M. Adcock Gert Folkerts Peter J. Barnes Arjan Paul Vos Johan Garssen |
| author_facet | Esmaeil Mortaz Ian M. Adcock Gert Folkerts Peter J. Barnes Arjan Paul Vos Johan Garssen |
| author_sort | Esmaeil Mortaz |
| collection | DOAJ |
| description | The physiology and pathology of the respiratory and gastrointestinal tracts are closely related. This similarity between the two organs may underlie why dysfunction in one organ may induce illness in the other. For example, smoking is a major risk factor for COPD and IBD and increases the risk of developing Crohn’s disease. Probiotics have been defined as “live microorganisms which, when administered in adequate amounts, confer health benefits on the host.” In model systems probiotics regulate innate and inflammatory immune responses. Commonly used probiotics include lactic acid bacteria, particularly Lactobacillus, Bifidobacterium, and Saccharomyces, and these are often used as dietary supplements to provide a health benefit in gastrointestinal diseases including infections, inflammatory bowel disease, and colon cancer. In this respect, probiotics probably act as immunomodulatory agents and activators of host defence pathways which suggest that they could influence disease severity and incidence at sites distal to the gut. There is increasing evidence that orally delivered probiotics are able to regulate immune responses in the respiratory system. This review provides an overview of the possible role of probiotics and their mechanisms of action in the prevention and treatment of respiratory diseases. |
| format | Article |
| id | doaj-art-b0a5f8ce73cf43dc8932b9edb29bd530 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-b0a5f8ce73cf43dc8932b9edb29bd5302025-08-20T03:39:15ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/751068751068Probiotics in the Management of Lung DiseasesEsmaeil Mortaz0Ian M. Adcock1Gert Folkerts2Peter J. Barnes3Arjan Paul Vos4Johan Garssen5Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The NetherlandsAirways Disease Section, National Heart and Lung Institute, Imperial College London, London, UKDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The NetherlandsAirways Disease Section, National Heart and Lung Institute, Imperial College London, London, UKDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The NetherlandsDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The NetherlandsThe physiology and pathology of the respiratory and gastrointestinal tracts are closely related. This similarity between the two organs may underlie why dysfunction in one organ may induce illness in the other. For example, smoking is a major risk factor for COPD and IBD and increases the risk of developing Crohn’s disease. Probiotics have been defined as “live microorganisms which, when administered in adequate amounts, confer health benefits on the host.” In model systems probiotics regulate innate and inflammatory immune responses. Commonly used probiotics include lactic acid bacteria, particularly Lactobacillus, Bifidobacterium, and Saccharomyces, and these are often used as dietary supplements to provide a health benefit in gastrointestinal diseases including infections, inflammatory bowel disease, and colon cancer. In this respect, probiotics probably act as immunomodulatory agents and activators of host defence pathways which suggest that they could influence disease severity and incidence at sites distal to the gut. There is increasing evidence that orally delivered probiotics are able to regulate immune responses in the respiratory system. This review provides an overview of the possible role of probiotics and their mechanisms of action in the prevention and treatment of respiratory diseases.http://dx.doi.org/10.1155/2013/751068 |
| spellingShingle | Esmaeil Mortaz Ian M. Adcock Gert Folkerts Peter J. Barnes Arjan Paul Vos Johan Garssen Probiotics in the Management of Lung Diseases Mediators of Inflammation |
| title | Probiotics in the Management of Lung Diseases |
| title_full | Probiotics in the Management of Lung Diseases |
| title_fullStr | Probiotics in the Management of Lung Diseases |
| title_full_unstemmed | Probiotics in the Management of Lung Diseases |
| title_short | Probiotics in the Management of Lung Diseases |
| title_sort | probiotics in the management of lung diseases |
| url | http://dx.doi.org/10.1155/2013/751068 |
| work_keys_str_mv | AT esmaeilmortaz probioticsinthemanagementoflungdiseases AT ianmadcock probioticsinthemanagementoflungdiseases AT gertfolkerts probioticsinthemanagementoflungdiseases AT peterjbarnes probioticsinthemanagementoflungdiseases AT arjanpaulvos probioticsinthemanagementoflungdiseases AT johangarssen probioticsinthemanagementoflungdiseases |